Cellestial Health is one of the preclinical-stage companies that was recently selected for a free consultation with the top experts at Leads to Development (L2D) regulatory consultancy, Jonathan Kearsey and Vincent Dubois. This will provide confidential guidance and advice on the path to the regulatory approval of the first Cellestial drug asset.
As Nat Hastings, CEO at Cellestial Health, says:
“Successful clinical trials start not at first-in-human, but with the very first experiment in cells. From the earliest stages of drug development, we must keep both regulatory pathways and patient benefit in mind. We’re grateful for L2D’s support in navigating this journey.”
This is exactly where Leads to Development experts thrive – helping ambitious startups translate innovative science into real clinical strategies that can succeed.
L2D’s cofounder, Jonathan Kearsey, adds:
“Attracting funding takes more than just a great scientific idea. Startups also need to show they have a clear, realistic, and regulatory-compliant path to the clinic. Cellestial brings the science and we’re thrilled to support them in planning a successful journey to and through clinical development.”
Nat Hastings and Saifur Rahman look forward to connecting with L2D for a 90-min strategic discussion to help map out our first drug asset’s course to the clinic.
For our colleagues with early data and big ambitions, get in touch with L2D directly for more support: jkearsey@leadstodevelopment.com.
The path to the clinic starts earlier than you think.